Management of iron deficiency anemia in inflammatory bowel disease - A practical approach

Annals of Gastroenterology

Volumn 26, Issue 2, 2013, Pages 104-113

  Stein, Jürgen ^a,c   Dignass, Axel U ^b,c  

^a KRANKENHAUS SACHSENHAUSEN   (Germany)

^b Head Department of Medicine I   (Germany)

^c Crohn Colitis Center Rhein Main   (Germany)

Author keywords

Anemia; Extraintestinal manifestations; Inflammatory bowel disease; Iron deficiency; Iron supplementation

Indexed keywords

ANTIANEMIC AGENT; C REACTIVE PROTEIN; CYANOCOBALAMIN; ERYTHROPOIETIN; FERRIC CARBOXYMALTOSE; FERRITIN; FERROUS GLUCONATE; FERUMOXYTOL; FOLIC ACID; HEMOGLOBIN; HEPCIDIN; IRON; IRON DEXTRAN; IRON ISOMALTOSIDE; IRON SACCHARATE; MONOFER; PLACEBO; PROTOPORPHYRIN ZINC; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ANAPHYLAXIS; ANEMIA; ANEMIA OF CHRONIC DISEASE; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; DELAYED HYPERSENSITIVITY; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EDEMA; ENTERITIS; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOPHOSPHATEMIA; HYPOTENSION; IRON BALANCE; IRON DEFICIENCY ANEMIA; IRON THERAPY; MAINTENANCE THERAPY; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; NONHUMAN; PATHOPHYSIOLOGY; RETICULOCYTE COUNT; RETICULOCYTE HEMOGLOBIN CONTENT; REVIEW; THROMBOSIS;

EID: 84875980096     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Gisbert JP, Gomollon F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol 2008;103:1299-1307.
2. Goodhand JR, Kamperidis N, Rao A, et al. Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. Inflamm Bowel Dis 2012;18:513-519.
3. Wiskin AE, Fleming BJ, Wootton SA, Beattie RM. Anaemia and iron deficiency in children with inflammatory bowel disease. J Crohns Colitis 2012;6:687-691.
4. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 2010;7:599-610.
5. Cartwright GE, Lauritsen MA, Humphreys S, Jones PJ, Merrill IM, Wintrobe MM. The Anemia Associated With Chronic Infection. Science 1946;103:72-73.
6. De Domenico I, Lo E, Ward DM, Kaplan J. Hepcidin-induced internalization of ferroportin requires binding and cooperative interaction with Jak2. Proc Natl Acad Sci U S A 2009;106:3800-3805.
7. De Domenico I, Ward DM, Langelier C, et al. The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol Biol Cell 2007;18:2569-2578.
8. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011;117:4425-4433.
9. Sullivan KM, Mei Z, Grummer-Strawn L, Parvanta I. Haemoglobin adjustments to define anaemia. Trop Med Int Health 2008;13:1267-1271.
10. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-1023.
11. Heimpel H, Diem H, Nebe T. [Counting reticulocytes: new importance of an old method]. Med Klin (Munich) 2010;105:538-543.
12. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007;13:1545-1553.
13. Metzgeroth G, Kripp M, Muller N, et al. The soluble transferring receptor (TfR)-F-Index is not applicable as a test for iron status in patients with chronic lymphocytic leukemia. Clin Chem Lab Med 2009;47:1291-1295.
14. Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta 2003;329:9-22.
15. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997;89:1052-1057.
16. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor, ferritin and TfR-F index in identification of latent iron deficiency. Eur J Haematol 1998;60:135-137.
17. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 2002;48:1066-1076.
18. Thomas C, Thomas L. Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol 2005;11:14-23.
19. Oustamanolakis P, Koutroubakis IE. Soluble transferrin receptorferritin index is the most efficient marker for the diagnosis of iron deficiency anemia in patients with IBD. Inflamm Bowel Dis 2011;17:E158-E159.
20. Oustamanolakis P, Koutroubakis IE. Soluble transferrin receptorferritin index in the evaluation of anemia in inflammatory bowel diesease: a case-control study. Ann Gastroenterol 2011;24:108-114.
21. Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. Clin Chem 2003;49:1573-1578.
22. Dagg JH, Goldberg A, Lochhead A. Value of erythrocyte protoporphyrin in the diagnosis of latent iron deficiency (sideropenia). Br J Haematol 1966;12:326-330.
23. Labbe RF, Dewanji A. Iron assessment tests: transferrin receptor vis-a-vis zinc protoporphyrin. Clin Biochem 2004;37:165-174.
24. Hastka J, Lasserre JJ, Schwarzbeck A, Strauch M, Hehlmann R. Zinc protoporphyrin in anemia of chronic disorders. Blood 1993;81:1200-1204.
25. Hwang C, Ross V, Mahadevan U. Micronutrient deficiencies in inflammatory bowel disease: From A to zinc. Inflamm Bowel Dis 2012;18:1961-1981.
26. Lomer MC, Cook WB, Jan-Mohamed HJ, et al. Iron requirements based upon iron absorption tests are poorly predicted by haematological indices in patients with inactive inflammatory bowel disease. Br J Nutr 2012;107:1806-1811.
27. Loitsch SM, Diehl D, Hartmann F, Dignass AU, Stein J. Impaired Intestinal Iron Absorption in Inflammatory Bowel Disease Correlates With Disease Activity and Markers of Inflammation but is Independent of Disease Location. Gastroenterology 2011;140:S5-S5.
28. Carrier J, Aghdassi E, Cullen J, Allard JP. Iron supplementation increases disease activity and vitamin E ameliorates the effect in rats with dextran sulfate sodium-induced colitis. J Nutr 2002;132:3146-3150.
29. Carrier J, Aghdassi E, Platt I, Cullen J, Allard JP. Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis. Aliment Pharmacol Ther 2001;15:1989-1999.
30. Erichsen K, Hausken T, Ulvik RJ, Svardal A, Berstad A, Berge RK. Ferrous fumarate deteriorated plasma antioxidant status in patients with Crohn disease. Scand J Gastroenterol 2003;38:543-548.
31. Munoz M, Gomez-Ramirez S, Garcia-Erce JA. Intravenous iron in inflammatory bowel disease. World J Gastroenterol 2009;15:4666-4674.
32. Bodemar G, Kechagias S, Almer S, Danielson BG. Treatment of anaemia in inflammatory bowel disease with iron sucrose. Scand J Gastroenterol 2004;39:454-458.
33. Gasche C, Dejaco C, Reinisch W, et al. Sequential treatment of anemia in ulcerative colitis with intravenous iron and erythropoietin. Digestion 1999;60:262-267.
34. Gasche C, Dejaco C, Waldhoer T, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Ann Intern Med 1997;126:782-787.
35. Katsanos K, Cavalier E, Ferrante M, et al. Intravenous iron therapy restores functional iron deficiency induced by infliximab. J Crohns Colitis 2007;1:97-105.
36. Schroder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005;100:2503-2509.
37. Schroder O, Schrott M, Blumenstein I, Jahnel J, Dignass AU, Stein J. A study for the evaluation of safety and tolerability of intravenous high-dose iron sucrose in patients with iron deficiency anemia due to gastrointestinal bleeding. Z Gastroenterol 2004;42:663-667.
38. Lindgren S, Wikman O, Befrits R, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluatorblind, multicentre study. Scand J Gastroenterol 2009;44:838-845.
39. Mamula P, Piccoli DA, Peck SN, Markowitz JE, Baldassano RN. Total dose intravenous infusion of iron dextran for iron-deficiency anemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002;34:286-290.
40. Koutroubakis IE, Oustamanolakis P, Karakoidas C, Mantzaris GJ, Kouroumalis EA. Safety and efficacy of total-dose infusion of low molecular weight iron dextran for iron deficiency anemia in patients with inflammatory bowel disease. Dig Dis Sci 2010;55:2327-2331.
41. Khalil A, Goodhand JR, Wahed M, Yeung J, Ali FR, Rampton DS. Efficacy and tolerability of intravenous iron dextran and oral iron in inflammatory bowel disease: a case-matched study in clinical practice. Eur J Gastroenterol Hepatol 2011;23:1029-1035.
42. Covic A, Mircescu G. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Nephrol Dial Transplant 2010;25:2722-2730.
43. Grimmelt AC, Cohen CD, Fehr T, Serra AL, Wuethrich RP. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Clin Nephrol 2009;71:125-129.
44. Anker SD, Colet JC, Filippatos G, et al. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 2009;11:1084-1091.
45. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-2448.
46. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009;49:2719-2728.
47. Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol 2008; 199:435 e1-e7.
48. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008;103:1182-1192.
49. Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011;141:846-853 e1-e2.
50. Gomollon F, Gisbert JP. IBD: Intravenous iron in IBD--what's the best preparation? Nat Rev Gastroenterol Hepatol 2011;8:477-478.
51. Balakrishnan VS, Rao M, Kausz AT, et al. Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest 2009;39:489-496.
52. Coyne DW. Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease. Expert Opin Pharmacother 2009;10:2563-2568.
53. Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program 2010;2010:338-347.
54. Bruining DH, Loftus EV, Jr. Technology Insight: new techniques for imaging the gut in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 2008;5:154-161.
55. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 2010;7:599-610.
56. Jahn MR, Andreasen HB, Futterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer(R)), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 2011;78:480-491.
57. Wikstrom B, Bhandari S, Barany P, et al. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. J Nephrol 2011;24:589-596.
58. Kulnigg S, Teischinger L, Dejaco C, Waldhor T, Gasche C. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol 2009;104:1460-1467.
59. Evstatiev R, Alexeeva O, Bokemeyer B, et al.; FERGI Study Group. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:269-277.
60. Moreno Lopez R, Sicilia Aladren B, Gomollon Garcia F. Use of agents stimulating erythropoiesis in digestive diseases. World J Gastroenterol 2009;15:4675-4685.
61. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-924.
62. Lippi G, Franchini M, Favaloro EJ. Thrombotic complications of erythropoiesis-stimulating agents. Semin Thromb Hemost 2010;36:537-549.
63. Locatelli F, Gascon P. Is nephrology more at ease than oncology with erythropoiesis-stimulating agents? Treatment guidelines and an update on benefits and risks. Oncologist 2009;14 (Suppl 1):57-62.